Method of administering azithromycin

Abstract

An oral dosage form of azithromycin which does not exhibit an adverse food effect; Specific azithromycin oral dosage forms including tablets, powders for oral suspensions and unit dose packets; Methods of treating microbial infections with the dosage forms; And therapeutic packages containing the dosage forms.

1. An oral dosage form of azithromycin which is in the form of a tablet made by wet granulation, which is administrable to a mammal that has eaten, which comprises azithromycin and a disintegrant, and which exhibits no adverse food effect, said dosage form effecting at least about 90% dissolution of azithromycin within about 30 minutes when an amount of the dosage form equivalent to 200 mg of azithromycin is tested as set forth in USP test <711> in a USP-2 dissolution apparatus under conditions at least as stringent as the following: 900 ml sodium phosphate buffer pH 6.0, 37° C., with paddles turning at 100 rpm, provided that said dosage form contains less than a taste-masking amount of an alkaline earth metal oxide or hydroxide. 
     
     
       2. A dosage form as defined in  claim 1 , wherein said mammal is a human. 
     
     
       3. A dosage form as defined in  claim 1 , further comprising a flavoring agent. 
     
     
       4. An oral dosage form of azithromycin which is in the form of a powder for oral suspension containing anhydrous buffer, which is administrable to a mammal that has eaten, which comprises azithromycin, one or more thickening agents, and said anhydrous buffer, and which exhibits no adverse food effect, said dosage form effecting at least about 90% dissolution of azithromycin within about 30 minutes when an amount of the dosage form equivalent to 200 mg of azithromycin is tested as set forth in USP test <711> in a USP-2 dissolution apparatus under conditions at least as stringent as the following: 900 ml sodium phosphate buffer, pH 6.0, 37° C., with paddles turning at 100 rpm, provided that said dosage form contains less than a taste-masking amount of an alkaline earth metal oxide or hydroxide. 
     
     
       5. A dosage form as defined in  claim 4 , wherein said mammal is a human. 
     
     
       6. A dosage form as defined in  claim 4 , further comprising a flavoring agent. 
     
     
       7. A dosage form as defined in  claim 6 , wherein said flavoring agent is a flavor system consisting of cherry, vanilla, and banana. 
     
     
       8. A dosage form as defined in  claim 4 , in the form of a suspension made from said powder. 
     
     
       9. An oral dosage form of azithromycin which is in the form of a unit dose packet containing a dispersing agent, which is administrable to a mammal that has eaten, which comprises azithromycin and said dispersing agent, and which exhibits no adverse food effect, said dosage form effecting at least about 90% dissolution of azithromycin within about 30 minutes when an amount of the dosage form equivalent to 200 mg of azithromycin is tested as set forth in USP test <711> in a USP-2 dissolution apparatus under conditions at least as stringent as the following: 900 ml sodium phosphate buffer, pH 6.0, 37° C., with paddles turning at 100 rpm, provided that said dosage form contains less than a taste-masking amount of an alkaline earth metal oxide or hydroxide. 
     
     
       10. A dosage form as defined in  claim 9 , wherein said mammal is a human. 
     
     
       11. A dosage form as defined in  claim 9 , further comprising an anhydrous buffer. 
     
     
       12. A dosage form as defined in  claim 9 , wherein said dispersing agent is colloidal silicon dioxide. 
     
     
       13. A dosage form as defined in  claim 9 , in the form of a suspension made from said unit dose packet. 
     
     
       14. An oral dosage form of azithromycin which is in the form of a tablet made by wet granulation, which is administrable to a mammal that has eaten, which comprises azithromycin and a disintegrant, and which exhibits no adverse food effect, said dosage form exhibiting a value of (AUC fed )/(AUC fst ) of at least 0.80 with a lower 90% confidence limit of at least 0.75, provided that said dosage form contains less than a taste-masking amount of an alkaline earth metal oxide or hydroxide. 
     
     
       15. A dosage form as defined in  claim 14 , wherein said mammal is a human. 
     
     
       16. A dosage form as defined in  claim 14 , further comprising a flavoring agent. 
     
     
       17. An oral dosage form of azithromycin which is in the form of a powder for oral suspension containing an anhydrous buffer, which is administrable to a mammal that has eaten, which comprises azithromycin, one or more thickening agents, and said anhydrous buffer, and which exhibits no adverse food effect, said dosage form exhibiting a value of (AUC fed )/(AUC fst ) of at least 0.80 with a lower 90% confidence limit of at least 0.75, provided that said dosage form contains less than a taste-masking amount of an alkaline earth metal oxide or hydroxide. 
     
     
       18. A dosage form as defined in  claim 17 , wherein said mammal is a human. 
     
     
       19. A dosage form as defined in  claim 17 , further comprising a flavoring agent. 
     
     
       20. A dosage form as defined in  claim 19 , wherein said flavoring agent is a flavoring system consisting of cherry, vanilla, and banana. 
     
     
       21. A dosage form as defined in  claim 17 , in the form of a suspension made from said powder. 
     
     
       22. An oral dosage form of azithromycin which is in the form of a unit dose packet containing a dispersing agent, which is administrable to a mammal that has eaten, which comprises azithromycin and said dispersing agent, and which exhibits no adverse food effect, said dosage form exhibiting a value of (AUC fed )/(AUC fst ) of at least 0.80 with a lower 90% confidence limit of at least 0.75, provided that said dosage form contains less than a taste-masking amount of an alkaline earth metal oxide or hydroxide. 
     
     
       23. A dosage form as defined in  claim 22 , wherein said mammal is a human. 
     
     
       24. A dosage form as defined in  claim 22 , further comprising an anhydrous buffer. 
     
     
       25. A dosage form as defined in  claim 22 , wherein said dispersing agent is colloidal silicon dioxide. 
     
     
       26. A dosage form as defined in  claim 22 , in the form of a suspension made from said unit dose packet. 
     
     
       27. A dosage form as defined in  claim 1 , comprising:
 58.2% azithromycin dihydrate;    6.0% pregelatinized starch;    30.9% anhydrous dibasic calcium phosphate;    2.0% sodium croscarmellose; and    2.9% lubricant.    
     
     
       28. A dosage form as defined in  claim 1 , comprising:
 58.2% azithromycin dihydrate;    11.1% pregelatinized starch;    25.7% anhydrous dibasic calcium phosphate;    2.0% sodium croscarmellose; and    2.9% lubricant.    
     
     
       29. A dosage form as defined in  claim 1 , comprising:
 58.2% azithromycin dihydrate;    3.1% pregelatinized starch;    31.3% anhydrous dibasic calcium phosphate;    4.4% sodium croscarmellose; and    2.9% lubricant.    
     
     
       30. A dosage form as defined in  claim 1 , comprising:
 58.2% azithromycin dihydrate;    11.1% pregelatinized starch;    23.3% anhydrous dibasic calcium phosphate;    4.4% sodium croscarmellose; and    2.9% lubricant.    
     
     
       31. A dosage form as defined in  claim 1 , comprising:
 58.2% azithromycin dihydrate;    3.1% maize starch;    33.8% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    2.0% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       32. A dosage form as defined in  claim 1 , comprising:
 58.2% azithromycin dihydrate;    6.0% maize starch;    30.9% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    2.0% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       33. A dosage form as defined in  claim 1 , comprising:
 58.2% azithromycin dihydrate;    11.1% maize starch;    25.7% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    2.0% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       34. A dosage form as defined in  claim 1 , comprising:
 58.2% azithromycin dihydrate;    3.1% maize starch;    31.3% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    4.4% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       35. A dosage form as defined in  claim 1 , comprising:
 58.2% azithromycin dihydrate;    6.0% maize starch;    32.2% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    0.7% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       36. A dosage form as defined in  claim 1 , comprising:
 58.2% azithromycin dihydrate;    6.0% maize starch;    28.4% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    4.4% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       37. A dosage form as defined in  claim 4 , comprising:
 5.0% azithromycin dihydrate;    92.5% sucrose;    0.4% anhydrous tribasic sodium phosphate;    0.2% hydroxypropylcellulose;    0.2% xanthan gum;    trace coloring; and    1.8% flavoring.    
     
     
       38. A dosage form as defined in  claim 4 , comprising:
 4.8% azithromycin dihydrate;    58.0% sucrose;    29.0% sorbitol;    1.9% anhydrous sodium carbonate;    0.4% sodium benzoate;    1.5% tragacanth gum powder;    1.5% titanium dioxide;    1.15% colloidal silicon dioxide;    0.6% glycine; and    2.3% flavoring.    
     
     
       39. A dosage form as defined in  claim 4 , comprising:
 5.0% azithromycin dihydrate;    91.8% sucrose;    0.4% anhydrous tribasic sodium phosphate;    0.2% hydroxypropylcellulose;    0.2% xanthan gum;    0.1% colloidal silicon dioxide;    0.6% glycine;    trace coloring; and    1.8% flavoring.    
     
     
       40. A dosage form as defined in  claim 4 , comprising:
 5.0% azithromycin dihydrate;    92.5% sucrose;    0.4% anhydrous tribasic sodium phosphate;    0.3% sodium carboxymethylcellulose;    trace coloring; and    1.8% flavoring.    
     
     
       41. A dosage form as defined in  claim 4 , comprising:
 5.0% azithromycin dihydrate;    90.4% sorbitol;    1.8% anhydrous sodium carbonate;    0.3% sodium carboxymethylcellulose;    0.1% colloidal silicon dioxide;    0.6% glycine;    trace coloring; and    1.8% flavoring.    
     
     
       42. A dosage from as defined in  claim 4 , comprising:
 5.0% azithromycin dihydrate;    46.3% sorbitol;    46.3% sucrose;    0.4% anhydrous tribasic sodium phosphate;    0.2% hydroxypropylmethylcellulose;    0.2% xanthan gum; and    trace coloring    1.8% flavoring.    
     
     
       43. A dosage form as defined in  claim 4 , comprising:
 5.0% azithromycin dihydrate;    45.7% sucrose;    45.7% sorbitol;    0.9% anhydrous sodium carbonate;    0.2% anhydrous tribasic sodium phosphate;    0.1% hydroxypropylmethylcellulose;    0.1% xanthan gum;    0.1% sodium carboxymethylcellulose;    0.1% colloidal silicon dioxide;    0.3% glycine;    trace coloring; and    1.8% flavoring.    
     
     
       44. A dosage form as defined in  claim 9 , comprising:
 9.5% azithromycin dihydrate;    88.2% sucrose;    0.8% anhydrous tribasic sodium phosphate;    0.5% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       45. A dosage form as defined in  claim 9 , comprising:
 9.5% azithromycin dihydrate;    88.2% sorbitol;    0.8% anhydrous tribasic sodium phosphate;    0.5% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       46. A dosage form as defined in  claim 9 , comprising:
 9.6% azithromycin dihydrate;    88.9% sucrose;    0.4% anhydrous tribasic sodium phosphate;    0.2% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       47. A dosage form as defined in  claim 9 , comprising:
 9.3% azithromycin dihydrate;    86.1% sucrose;    1.8% anhydrous tribasic sodium phosphate;    2.0% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       48. A dosage form as defined in  claim 9 , comprising:
 16.7% azithromycin dihydrate;    79.5% sucrose;    1.4% anhydrous tribasic sodium phosphate;    0.9% colloidal silicon dioxide; and    1.6% flavoring.    
     
     
       49. A dosage form as defined in  claim 9 , comprising:
 9.5% azithromycin dihydrate;    44.1% sucrose;    44.1% sorbitol;    0.8% anhydrous tribasic sodium phosphate;    0.5% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       50. A dosage form as defined in  claim 9 , comprising:
 9.5% azithromycin dihydrate;    44.1% sucrose;    44.1% sorbitol;    0.4% anhydrous tribasic sodium phosphate;    0.2% anhydrous sodium carbonate;    0.2% glycine;    0.5% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       51. A dosage form as defined in  claim 14 , comprising:
 58.2% azithromycin dihydrate;    6.0% pregelatinized starch;    30.9% anhydrous dibasic calcium phosphate;    2.0% sodium croscarmellose; and    2.9% lubricant.    
     
     
       52. A dosage form as defined in  claim 14 , comprising:
 58.2% azithromycin dihydrate;    11.1% pregelatinized starch;    25.7% anhydrous dibasic calcium phosphate;    2.0% sodium croscarmellose; and    2.9% lubricant.    
     
     
       53. A dosage form as defined in  claim 14 , comprising:
 58.2% azithromycin dihydrate;    3.1% pregelatinized starch;    31.3% anhydrous dibasic calcium phosphate;    4.4% sodium croscarmellose; and    2.9% lubricant.    
     
     
       54. A dosage form as defined in  claim 14 , comprising:
 58.2% azithromycin dihydrate;    11.1% pregelatinized starch;    23.3% anhydrous dibasic calcium phosphate;    4.4% sodium croscarmellose; and    2.9% lubricant.    
     
     
       55. A dosage form as defined in  claim 14 , comprising:
 58.2% azithromycin dihydrate;    3.1% maize starch;    33.8% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    2.0% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       56. A dosage form as defined in  claim 14 , comprising:
 58.2% azithromycin dihydrate;    6.0% maize starch;    30.9% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    2.0% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       57. A dosage form as defined in  claim 14 , comprising:
 58.2% azithromycin dihydrate;    11.1% maize starch;    25.7% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    2.0% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       58. A dosage form as defined in  claim 14 , comprising:
 58.2% azithromycin dihydrate;    3.1% maize starch;    31.3% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    4.4% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       59. A dosage form as defined in  claim 14 , comprising:
 58.2% azithromycin dihydrate;    6.0% maize starch;    32.2% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    0.7% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       60. A dosage form as defined in  claim 14 , comprising:
 58.2% azithromycin dihydrate;    6.0% maize starch;    28.4% dibasic calcium phosphate, lactose, or microcrystalline cellulose;    4.4% sodium starch glycolate or crosslinked polyvinylpyrrolidone; and    2.9% lubricant.    
     
     
       61. A dosage form as defined in  claim 17 , comprising:
 5.0% azithromycin dihydrate;    92.5% sucrose;    0.4% anhydrous tribasic sodium phosphate;    0.2% hydroxypropylcellulose;    0.2% xanthan gum;    trace coloring; and    1.8% flavoring.    
     
     
       62. A dosage form as defined in  claim 17 , comprising:
 4.8% azithromycin dihydrate;    58.0% sucrose;    29.0% sorbitol;    1.9% anhydrous sodium carbonate;    0.4% sodium benzoate;    1.5% tragacanth gum powder;    1.5% titanium dioxide;    1.15% colloidal silicon dioxide;    0.6% glycine; and    2.3% flavoring.    
     
     
       63. A dosage form as defined in  claim 17 , comprising:
 5.0% azithromycin dihydrate;    91.8% sucrose;    0.4% anhydrous tribasic sodium phosphate;    0.2% hydroxypropylcellulose;    0.2% xanthan gum;    0.1% colloidal silicon dioxide;    0.6% glycine;    trace coloring; and    1.8% flavoring.    
     
     
       64. A dosage form as defined in  claim 17 , comprising:
 5.0% azithromycin dihydrate;    92.5% sucrose;    0.4% anhydrous tribasic sodium phosphate;    0.3% sodium carboxymethylcellulose;    trace coloring; and    1.8% flavoring.    
     
     
       65. A dosage form as defined in  claim 17 , comprising:
 5.0% azithromycin dihydrate;    90.4% sorbitol;    1.8% anhydrous sodium carbonate;    0.3% sodium carboxymethylcellulose;    0.1% colloidal silicon dioxide;    0.6% glycine;    trace coloring; and    1.8% flavoring.    
     
     
       66. A dosage form as defined in  claim 17 , comprising:
 5.0% azithromycin dihydrate;    46.3% sorbitol;    46.3% sucrose;    0.4% anhydrous tribasic sodium phosphate;    0.2% hydroxypropylmethylcellulose;    0.2% xanthan gum; and    trace coloring    1.8% flavoring.    
     
     
       67. A dosage form as defined in  claim 17 , comprising:
 5.0% azithromycin dihydrate;    45.7% sucrose;    45.7% sorbitol;    0.9% anhydrous sodium carbonate;    0.2% anhydrous tribasic sodium phosphate;    0.1% hydroxypropylmethylcellulose;    0.1% xanthan gum;    0.1% sodium carboxymethylcellulose;    0.1% colloidal silicon dioxide;    0.3% glycine;    trace coloring; and    1.8% flavoring.    
     
     
       68. A dosage form as defined in  claim 22 , comprising:
 9.5% azithromycin dihydrate;    88.2% sucrose;    0.8% anhydrous tribasic sodium phosphate;    0.5% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       69. A dosage form as defined in  claim 22 , comprising:
 9.5% azithromycin dihydrate;    88.2% sorbitol;    0.8% anhydrous tribasic sodium phosphate;    0.5% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       70. A dosage form as defined in  claim 22 , comprising:
 9.6% azithromycin dihydrate;    88.9% sucrose;    0.4% anhydrous tribasic sodium phosphate;    0.2% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       71. A dosage form as defined in  claim 22 , comprising:
 9.3% azithromycin dihydrate;    86.1% sucrose;    1.8% anhydrous tribasic sodium phosphate;    2.0% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       72. A dosage form as defined in  claim 22 , comprising:
 16.7% azithromycin dihydrate;    79.5% sucrose;    1.4% anhydrous tribasic sodium phosphate;    0.9% colloidal silicon dioxide; and    1.6% flavoring.    
     
     
       73. A dosage form as defined in  claim 22 , comprising:
 9.5% azithromycin dihydrate;    44.1% sucrose;    44.1% sorbitol;    0.8% anhydrous tribasic sodium phosphate;    0.5% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       74. A dosage form as defined in  claim 22 , comprising:
 9.5% azithromycin dihydrate;    44.1% sucrose;    44.1% sorbitol;    0.4% anhydrous tribasic sodium phosphate;    0.2% anhydrous sodium carbonate;    0.2% glycine;    0.5% colloidal silicon dioxide; and    0.9% flavoring.    
     
     
       75. A therapeutic package, comprising
 a container,    
       an oral dosage form of azithromycin which exhibits either or both of:
   (a) at least about 90% dissolution of azithromycin within about 30 minutes when an amount of the dosage form equivalent to 200 mg of azithromycin is tested as set forth in USP test <711> in a USP-2 dissolution apparatus under conditions at least as stringent as the following: 900 ml sodium phosphate buffer, pH 6.0, 37° C., with paddles turning at 100 rpm; and/or    (b) a value of (AUC fed )/(AUC fst ) of at least 0.80 with a lower 90% confidence limit of at least 0.75,    
 and, associated with said package, written matter non-limited as to whether the dosage form can be taken with or without food.  
 
     
     
       76. A therapeutic package as defined in  claim 75 , wherein said dosage form is in the form of a tablet. 
     
     
       77. A therapeutic package as defined in  claim 75 , wherein said dosage form is in the form of a powder for oral suspension. 
     
     
       78. A therapeutic package as defined in  claim 77 , wherein said dosage form is in the form of a suspension made from said powder. 
     
     
       79. A therapeutic package as defined in  claim 75 , wherein said dosage form is in the form of a unit dose packet. 
     
     
       80. A therapeutic package as defined in  claim 79 , wherein said dosage form is in the form of a suspension made from said unit dose packet. 
     
     
       81. A method for treating a microbial infection in a mammal which comprises administering, to a mammal that has eaten food of any sort within one hour prior to dosing, in need of such treatment, an antimicrobially effective amount of azithromycin in an oral dosage form which exhibits either or both of:
 (a) at least about 90% dissolution of azithromycin within about 30 minutes when an amount of the dosage form equivalent to 200 mg of azithromycin is tested as set forth in USP test <711> in a USP-2 dissolution apparatus under conditions at least as stringent as the following: 900 ml sodium phosphate buffer, pH 6.0, 37° C., with paddles turning at 100 rpm; and/or  
 (b) a value of (AUC fed )/(AUC fst ) of at least 0.80 with a lower 90% confidence limit of at least 0.75.  
 
     
     
       82. A method as defined in  claim 81 , wherein said mammal is a human. 
     
     
       83. A method as defined in  claim 82 , wherein said dosage form exhibits a value of (AUC fed )/(AUC fst ) of at least 0.80 with a lower 90% confidence limit of at least 0.75. 
     
     
       84. A method as defined in  claim 82 , wherein said dosage form is in the form of a tablet. 
     
     
       85. A method as defined in  claim 82 , wherein said dosage form is in the form of a powder for oral suspension. 
     
     
       86. A method as defined in  claim 85 , wherein said dosage form is in the form of a suspension made from said powder. 
     
     
       87. A method as defined in  claim 82 , wherein said dosage form is in the form of a unit dose packet. 
     
     
       88. Method as defined in  claim 87 , wherein said dosage form is in the form of a suspension made from said unit dose packet. 
     
     
       89. A method as defined in  claim 83 , wherein said dosage form is in the form of a tablet. 
     
     
       90. A method as defined in claim  89   83 , wherein said dosage form is in the form of a powder for oral suspension. 
     
     
       91. A method as defined in  claim 90 , wherein said dosage form is in the form of a suspension made from said powder. 
     
     
       92. A method as defined in  claim 83 , wherein said dosage form is in the form of a unit dose packet. 
     
     
       93. A method as defined in  claim 92 , wherein said dosage form is in the form of a suspension made from said unit dose packet. 
     
     
       94. A package as defined in  claim 75 , wherein said dosage form exhibits a value of (AUC fed )/(AUC fst ) of at least 0.80 with a lower 90% confidence limit of at least 0.75. 
     
     
       95. A package as defined in  claim 94 , wherein said dosage form is in the form of a tablet. 
     
     
       96. A package as defined in  claim 94  wherein said dosage form is in the form of a powder for oral suspension. 
     
     
       97. A package as defined in  claim 96 , wherein said dosage form is in the form of a suspension made from said powder. 
     
     
       98. A package as defined in  claim 94 , wherein said dosage form is in the form of a unit dose packet. 
     
     
       99. A package as defined in  claim 98 , wherein said dosage form is in the form of a suspension made from said unit dose packet. 
     
     
       100. A method as defined in  claim 81 , wherein said mammal has eaten food of any sort within  30  minutes prior to dosing azithromycin.